{
  "nctId": "NCT02169830",
  "briefTitle": "Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine",
  "officialTitle": "A Prospective Randomized Cross-over Trial of Nortryptyline and Topiramate in the Initial Treatment of Vestibular Migraine.",
  "protocolDocument": {
    "nctId": "NCT02169830",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-10-10",
    "uploadDate": "2020-08-17T16:28",
    "size": 329141,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02169830/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 35,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2014-08-22",
    "completionDate": "2019-10-30",
    "primaryCompletionDate": "2019-10-30",
    "firstSubmitDate": "2014-06-17",
    "firstPostDate": "2014-06-23"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n-Men and women aged 18 to 70 with untreated vestibular migraine variant as diagnosed by history.\n\nExclusion Criteria:\n\n* Patients with allergies to nortriptyline or topiramate and their analogs or medication interactions that preclude their use.\n* Patients under the care of a psychiatrist.\n* Patients who are pregnant or trying to become pregnant.\n* Patients taking more than 5 prescription medications.\n* Patients with cancer.\n* Patient has a history of immunodeficiency.\n* Patient has a history of substance abuse within the preceding 6 months prior to screening.\n* Patient has used an investigational drug or device in the the 3 months prior to screening.\n* Patient is using marijuana for medical or other uses.\n* Patient has any other clinically significant illness or medical condition that, in the investigator's opinion, would prohibit the subject from participating in the study.\n* Patient with traumatic brain injury.\n* Patients taking Nortriptyline, MAOIs\n* Patients with liver or kidney dysfunction or glaucoma\n\nDue to know drug interactions, patients taking the following medications will be excluded.\n\nNortriptyline: monoamine oxidase inhibitors (MAO) such as phenelzine. Patients on oral contraceptives will be asked to use a secondary method as nortriptyline can reduce the effectiveness of oral contraceptives.\n\nTopiramate: acetazolamide (kidney stones), digoxin\n\nExclude subjects with liver dysfunction, kidney dysfunction and glaucoma (per the risks associated with topiramate).",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "70 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Evaluate the Comparative Effectiveness of Migraine Diet, Nortriptyline and Topiramate",
        "description": "Changes in Migraine Specific Quality of LIfe (MSQ) and Dizziness Handicap Inventory (DHI) between groups",
        "timeFrame": "one year"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 24,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:29:53.784Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}